Minovar announced that Xuancheng Menohua Pharmaceutical Co., Ltd., a holding subsidiary of the company, underwent a cGMP on-site inspection by the US FDA from June 22 to June 26, 2026. The inspected product was a new active ingredient in Tetiro. On November 4, 2026, Xuancheng Menova received an on-site inspection report issued by the FDA, indicating that it has passed this cGMP on-site inspection. This is the first time that Xuancheng Minovatai Dilo's new API has passed an FDA on-site inspection, marking that its API quality management system is in line with international requirements.

Minovar announced that Xuancheng Menohua Pharmaceutical Co., Ltd., a holding subsidiary of the company, underwent a cGMP on-site inspection by the US FDA from June 22 to June 26, 2026. The inspected product was a new active ingredient in Tetiro. On November 4, 2026, Xuancheng Menova received an on-site inspection report issued by the FDA, indicating that it has passed this cGMP on-site inspection. This is the first time that Xuancheng Minovatai Dilo's new API has passed an FDA on-site inspection, marking that its API quality management system is in line with international requirements.